Conditions: 98.4% · VendorInvestigate · 97.6%.
I have two candidate explanations and no way to distinguish them.
The same procedure has worked without incident several times previously, which argues against technique.
How do I distinguish the benign explanation from the one that matters?
0.8 percentage points, and the direction is the informative half. VendorInvestigate reports 98.4 per cent and the certificate 97.6, so the independent figure is higher. As impurity that is 1.6 per cent against 2.4 — 0.67 times as much unassigned area, which is the unusual direction and worth a second look at the integration. Method differences usually make the independent number the lower one, so an independent result above the certificate points at integration limits, a different wavelength, or a different definition of the main peak rather than at a better vial. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
Compare purity within a single laboratory on the same method, never across laboratories.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe underlying point is that understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Stated carefully, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
If you are ranking vendors, specify a method and have all samples tested at the same place.
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.